Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Comparison of the pre- and post-change Aranesp batches measured by capillary zone electrophoresis.
Figure 2: Comparison of the different pre- and post-change batches of Rituxan/Mabthera.
Figure 3: Comparison of the different pre- and post-change batches of Enbrel.

References

  1. Chirino, A.J & Mire-Sluis, A. Nat. Biotechnol. 22, 1383–1391 (2004).

    Article  CAS  Google Scholar 

  2. Egrie, J.C., Dwyer, E., Browne, J.K., Hitz, A. & Lykos, M.A. Exp. Hematol. 31, 290–299 (2003).

    Article  CAS  Google Scholar 

  3. Egrie, J.C. & Browne, J.K. Br. J. Cancer 84, 3–10 (2001).

    Article  CAS  Google Scholar 

  4. European Public Assessment Report Variation, Aranesp-H-332-X-42 (2008) http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000332/human_med_000651.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124#

  5. Glennie, M.J., French, R.R., Cragg, M.S. & Taylor R.P. Mol. Immunol. 44, 3823–3837 (2007).

    Article  CAS  Google Scholar 

  6. Reslan, L., Dalle, S. & Dumontet, C. MAbs 1, 222–229 (2009).

    Article  Google Scholar 

  7. Dick, L.W., Kim, C., Qiu, D. & Cheng, K.-C. Biotechnol. Bioeng. 97, 544–553 (2007).

    Article  CAS  Google Scholar 

  8. Antes, B. et al. J. Chromatogr. B 852, 250–256 (2007).

    Article  CAS  Google Scholar 

  9. Shields, R.L. et al. J. Biol. Chem. 277, 26733–26740 (2002).

    Article  CAS  Google Scholar 

  10. Tracey, D. et al. Pharmacol. Ther. 117, 244–279 (2008).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

NK3.3 cell line was generated by J. Kornbluth, St. Louis University School of Medicine, and the cell line was obtained by Novartis from St. Louis University, St. Louis. We would like to thank J. Windisch, M. McCamish, C. Sonderegger, M. Lang-Salchner and A. Seidl from Sandoz Biopharmaceuticals for their thorough review and support.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The authors are employees of Novartis/Sandoz, which is developing, manufacturing and marketing biopharmaceuticals, including biosimilar products.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1—3, Supplementary Tables 1,2 and Supplementary Methods (PDF 439 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schiestl, M., Stangler, T., Torella, C. et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29, 310–312 (2011). https://doi.org/10.1038/nbt.1839

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1839

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research